Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV‐1‐infected patients: a cohort study1. Issue 2 (15th August 2014)

• Record Type: Journal Article
• Authors: Gantner, P; Reinhart, S; Partisani, M; Baldeyrou, M; Batard, M‐L; Bernard‐Henry, C; Cheneau, C; de Mautort, E; Priester, M; Fafi‐Kremer, S; Muret, P; Rey, D
• Is Part Of: HIV medicine. Volume 16:Issue 2(2015:Feb.)
• Page Start: 132
• Page End: 136
• Publication Date: 2014-08-15
• Subjects: HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.12183
• Languages: English
• ISSNs: 1464-2662

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hiv12183-sec-0001" sec-type="section"> <title>Objectives</title> <p>Emtricitabine/tenofovir/rilpivirine as a single‐tablet regimen (STR) is widely used without licence in treatment‐experienced patients. The purpose of this retrospective observational study was to assess viral suppression of ART‐experienced patients switching to STR.</p> </sec> <sec id="hiv12183-sec-0002" sec-type="section"> <title>Methods</title> <p>We assessed 131 pretreated patients switching to STR with HIV RNA < 400 HIV‐1 RNA copies/mL. The primary outcome measure was the proportion of patients at week 24 with HIV RNA < 40 copies/mL.</p> </sec> <sec id="hiv12183-sec-0003" sec-type="section"> <title>Results</title> <p>By week 24, eight patients had stopped STR: four because of adverse events and four for other reasons. Three virological failures were observed; among these, at least one patient developed cross‐resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs), in particular with the E138K pattern. In intent‐to‐treat analysis, 92% of participants (120 of 131) achieved HIV RNA < 40 copies/mL. Only grade 1 to 2 adverse events were observed, mainly consisting of increased liver enzymes (n = 33). Systemic exposure to rilpivirine was above the usually observed steady‐state levels for the 18 measurements assessed.</p> </sec> <sec id="hiv12183-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Efficacy and tolerability are similar to those in treatment‐naïve patients.</p> </sec> </abstract>